Boehringer Ingelheim widens its kidney-disease p
Author: Michael
A two-year partnership with Ultrahuman aims to c
GPX4-targeting therapy reduces epigenetic age ma
Rubedo Life Sciences released Phase 1b clinical f
Function and Google Health announced a partnershi
Immorta Bio completed planned preclinical studies
Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well beyond glucose. There is a neat irony in a fingerstick company funding the device that might make fingersticks unnecessary. Ascensia Diabetes Care, maker of the CONTOUR blood glucose meters, has led a $36 million Series B in Sava Technologies, the London healthtech whose microsensor reads glucose from just beneath the skin. It has also agreed to commercialize and distribute the device in Europe once it is approved – which suggests Ascensia sees more future in the sensor than in defending…
MUST’s RETRO-EPIGERNA team won $1 million and
A new partnership is combining a blood test, a c
Neither the FDA nor EMA recognizes aging as an i